New and established tyrosine kinase inhibitors for chronic myeloid leukemia

Drugs of Today

Volumn 48, Issue 9, 2012, Pages 601-613

  Thienelt, C D ^a,b   Green, K ^a   Bowles, Daniel W ^a,b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

BCR ABL fusion protein; Chronic myeloid leukemia; Philadelphia chromosome; Tyrosine kinase inhibitors

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; BOSUTINIB; CYTARABINE; DASATINIB; IMATINIB; LEVOTHYROXINE; LIVE VACCINE; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; TASINGA; UNCLASSIFIED DRUG; 4 METHYL N (3 (4 METHYLIMIDAZOL 1 YL) 5 (TRIFLUOROMETHYL)PHENYL) 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)BENZAMIDE; 4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; ANILINE DERIVATIVE; NITRILE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; QUINOLINE DERIVATIVE; THIAZOLE DERIVATIVE;

ALOPECIA; ANEMIA; ARTHRALGIA; BLEEDING; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CARDIOMEGALY; CARDIOTOXICITY; CHROMOSOME 22; CHROMOSOME 9; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; EDEMA; FATIGUE; FEVER; FOLLOW UP; GENE MUTATION; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; LONG QT SYNDROME; MUSCLE CRAMP; MUSCLE SPASM; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING; DRUG ANTAGONISM;

ANILINE COMPOUNDS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NITRILES; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; QUINOLINES; THIAZOLES;

EID: 84868643945     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2012.48.9.1869590     Document Type: Review

References (69)

1. Siegel, R., Naishadham, D., Jemal, A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1): 10-29.
2. Kantarjian, H.M., Dixon, D., Keating, M.J., Talpaz, M., Walters, R.S., McCredie, K.B., Freireich, E.J. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988, 61(7): 1441-6. (Pubitemid 18076421)
3. Sokal, J.E., Baccarani, M., Russo, D., Tura, S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988, 25(1): 49-61.
4. Vardiman, J.W., Harris, N.L., Brunning, R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100(7): 2292-302.
5. Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., Kantarjian, H.M. The biology of chronic myeloid leukemia. N Engl J Med 1999, 341(3): 164-72. (Pubitemid 29325745)
6. Goldman, J.M., Melo, J.V. Chronic myeloid leukemia -Advances in biology and new approaches to treatment. N Engl J Med 2003, 349(15): 1451-64. (Pubitemid 37211061)
7. Jabbour, E., Kantarjian, H.M., Abruzzo, L.V. et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007, 110(8): 2991-5. (Pubitemid 350006953)
8. Baccarani, M., Saglio, G., Goldman, J. et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006,108(6): 1809-20. (Pubitemid 44394987)
9. Lima, L., Bernal-Mizrachi, L., Saxe, D. et al. Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer 2011, 117(6): 1245-52.
10. Imatinib meslylate [package insert]. 2012 [cited 2012 July 18]; Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/021588s035lbl. pdf
11. Dasatinib [package inisert]. 2010 [cited 2012 July 16]; Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/021986s7s8lbl.pdf
12. Nilotinib [package insert]. 2010 [cited; Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/022068s004s005lbl.pdf
13. Vigneri, P., Wang, J.Y. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCRABL tyrosine kinase. Nat Med 2001, 7(2): 228-34. (Pubitemid 32148491)
14. Asaki, T., Sugiyama, Y., Hamamoto, T., Higashioka, M., Umehara, M., Naito, H.,Niwa, T. Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors. Bioorg Med Chem Lett 2006, 16(5): 1421-5. (Pubitemid 43143035)
15. Leveque, D., Maloisel, F. Clinical pharmacokinetics of imatinib mesylate. In Vivo 2005, 19(1): 77-84. (Pubitemid 40450380)
16. Scheinfeld, N. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases. J Drugs Dermatol 2006, 5(2): 117-22.
17. Haouala, A., Widmer, N., Duchosal, M.A., Montemurro, M., Buclin, T., Decosterd, L.A. Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib. Blood 2011, 117(8): e75-87.
18. O'Brien, S.G., Guilhot, F., Larson, R.A. et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003, 348(11): 994-1004. (Pubitemid 36302244)
19. Hughes, T.P., Kaeda, J., Branford, S. et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003, 349(15): 1423-32. (Pubitemid 37211057)
20. Druker, B.J., Guilhot, F., O'Brien, S.G. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355(23): 2408-17. (Pubitemid 44903745)
21. Cortes, J.E., Baccarani, M., Guilhot, F. et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: Tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010, 28(3): 424-30.
22. Baccarani, M., Rosti, G., Castagnetti, F. et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: A European LeukemiaNet Study. Blood 2009, 113(19): 4497-504.
23. th Annu Meet Am Soc Clin Oncol (ASCO) (June 4-8, Chicago) 2010] 2010, 28(15, Suppl.): Abst 6517.
24. Preudhomme, C., Guilhot, J., Nicolini, F.E. et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010, 363(26): 2511-21.
25. Mahon, F.X., Rea, D., Guilhot, J. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010, 11(11): 1029-35.
26. Talpaz, M., Silver, R.T., Druker, B.J. et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002, 99(6): 1928-37. (Pubitemid 34525471)
27. Talpaz, M., Shah, N.P., Kantarjian, H. et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006, 354(24): 2531-41. (Pubitemid 43882349)
28. Kantarjian, H., Talpaz, M., O'Brien, S. et al. Survival benefit with imatinib mesylate therapy in patients with acceleratedphase chronic myelogenous leukemia - Comparison with historic experience. Cancer 2005, 103(10): 2099-108. (Pubitemid 40605118)
29. Mughal, T.I., Schrieber, A. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase. Biologics 2010, 4: 315-23.
30. Atallah, E., Durand, J.B., Kantarjian, H., Cortes, J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007, 110(4): 1233-7. (Pubitemid 47281421)
31. Noens, L., van Lierde, M.A., De Bock, R. et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood 2009, 113(22): 5401-11.
32. Ernst, T., Hochhaus, A. Chronic myeloid leukemia: Clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression. Semin Oncol 2012, 39(1): 58-66.
33. Donato, N.J., Wu, J.Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R., Talpaz, M. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003, 101(2): 690-8. (Pubitemid 36077594)
34. Hughes, T.P., Hochhaus, A., Branford, S. et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: An analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood 2010, 116(19): 3758-65.
35. th Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2012] 2012, 30(Suppl.): Abst 6510.
36. Tokarski, J.S., Newitt, J.A., Chang, C.Y. et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinibresistant ABL mutants. Cancer Res 2006, 66(11): 5790-7. (Pubitemid 43927133)
37. O'Hare, T., Walters, D.K., Stoffregen, E.P. et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65(11): 4500-5. (Pubitemid 40740783)
38. Hochhaus, A., Kantarjian, H.M., Baccarani, M. et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007, 109(6): 2303-9. (Pubitemid 46425867)
39. Kantarjian, H., Pasquini, R., Hamerschlak, N. et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: A randomized phase 2 trial. Blood 2007, 109(12): 5143-50. (Pubitemid 46890528)
40. Shah, N.P., Kim, D.W., Kantarjian, H. et al. Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010, 95(2): 232-40.
41. Guilhot, F., Apperley, J., Kim, D.W. et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 2007, 109(10): 4143-50. (Pubitemid 46743375)
42. Cortes, J., Rousselot, P., Kim, D.W. et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007, 109(8): 3207-13. (Pubitemid 46572505)
43. Kantarjian, H., Cortes, J., Kim, D.W. et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-Month median followup. Blood 2009, 113(25): 6322-9.
44. Kantarjian, H., Shah, N.P., Hochhaus, A. et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010, 362(24): 2260-70.
45. Quintas-Cardama, A., Kantarjian, H., Ravandi, F. et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 2009, 115(11): 2482-90.
46. Manley, P.W., Cowan-Jacob, S.W., Mestan, J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta 2005, 1754(1-2): 3-13. (Pubitemid 41797682)
47. Weisberg, E., Manley, P., Mestan, J., Cowan-Jacob, S., Ray, A., Griffin, J.D. AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL. Br J Cancer 2006, 94(12): 1765-9. (Pubitemid 43882564)
48. Yin, O.Q., Giles, F.J., Baccarani, M. et al. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemother Pharmacol 2012, 70(2): 345-50.
49. Kantarjian, H., Giles, F., Wunderle, L. et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354(24): 2542-51. (Pubitemid 43882350)
50. Kantarjian, H.M., Giles, F., Gattermann, N. et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110(10): 3540-6. (Pubitemid 350159618)
51. Giles, F.J., Coutre, P.L., Pinilla-Ibarz, J. et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-Month follow-up results of a phase II study. Leukemia 2012, Epub ahead of print.
52. le Coutre, P., Ottmann, O.G., Giles, F. et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008, 111(4): 1834-9. (Pubitemid 351451490)
53. le Coutre, P.D., Giles, F.J., Hochhaus, A. et al. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results. Leukemia 2012, 26(6): 1189-94.
54. Giles, F.J., Kantarjian, H.M., le Coutre, P.D. et al. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 2012, 26(5): 959-62.
55. Saglio, G., Kim, D.W., Issaragrisil, S. et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010, 362(24): 2251-9.
56. Kantarjian, H.M., Hochhaus, A., Saglio, G. et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011, 12(9): 841-51.
57. Puttini, M., Coluccia, A.M., Boschelli, F. et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006, 66(23): 11314-22. (Pubitemid 46009962)
58. Redaelli, S., Piazza, R., Rostagno, R. et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009, 27(3): 469-71.
59. Golas, J.M., Arndt, K., Etienne, C. et al. SKI-606, a 4-anilino- 3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003, 63(2): 375-81. (Pubitemid 36152495)
60. Abbas, R., Hug, B.A., Leister, C., Gaaloul, M.E., Chalon, S., Sonnichsen, D. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects. Cancer Chemother Pharmacol 2012, 69(1): 221-7.
61. Cortes, J.E., Kantarjian, H.M., Brummendorf, T.H. et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 2011, 118(17): 4567-76.
62. Khoury, H.J., Cortes, J.E., Kantarjian, H.M. et al. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood 2012, 119(15): 3403-12.
63. rd Annu Meet Am Soc Hematol (Dec 10-13, San Diego) 2011] 2011, 118(21): Abst 445.
64. Gambacorti-Passerini, C., Lipton, J.H., Tee, G.Y. et al. BELA trial update: Bosutinib (BOS) versus imatinib (IM) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) after 30 months of follow-up. J Clin Oncol [48th Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2012] 2012, 30(Suppl.): Abst 6512.
65. Huang, W.S., Metcalf, C.A. Discovery of 3-[2-(imidazo[1,2- b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin- 1-y l)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 2010, 53(12): 4701-19.
66. O'Hare, T., Shakespeare, W.C., Zhu, X. et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009, 16(5): 401-12.
67. Cortes, J., Talpaz, M., Bixby, D. et al. A phase 1 trial of oral ponatinib (AP24534) in patients with refractory chronic myelogenous leukemia (CML) and other hematologic malignancies: Emerging safety and clinical response findings. Blood [52nd Annu Meet Am Soc Hematol (Dec 4-7, Orlando) 2010] 2010, 116(21): Abst 210.
68. rdAnnu Meet Am Soc Hematol (Dec 10-13, San Diego) 2011] 2011: 118(21): Abst 109.
69. th Annu Meet Am Soc Clin Oncol (ASCO) (June 1-5, Chicago) 2012] 2012, 30(Suppl.): Abst 6503.